Key facts
- Syncromune’s last known valuation is $254.0M (Aug 2025).
- It has raised $142.0M across 2 recorded rounds; the latest was Later Stage VC ($144.8M) in Dec 2024.
- Notable investors include Wasatch Health.
- Syncromune has filed 4 Form Ds with the SEC since 2022, most recently Aug 2025 ($111.8M sold to 77 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Syncromune
Funding rounds
2 roundsAbout Syncromune
Developer of intratumoral immunotherapy designed to treat metastatic solid tumor cancers. The company's immunotherapy utilizes intratumoral sync technology to synchronize the timing and location of tumor antigen release with the functional activation of immune cells, enabling patients to power a personalized autologous vaccine with their cancer antigens.
- Sector
- Healthcare
- HQ
- Fort Lauderdale, FL, United States
- Founded
- 2020
- Employees
- 33
- Website
- syncromune.com/
- Ownership
- Privately Held (backing)
Syncromune doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syncromune shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syncromune in its N-PORT filings yet. We sweep new filings monthly.